Erdem Bangi
Papers
2
Total Citations
145
H-Index
2
About
Erdem Bangi is a pioneering translational researcher whose work sits at the intersection of functional genomics, personalized oncology, and rare cancer therapeutics. His major contributions center on developing *in vivo* drug screening platforms that use living organisms to identify effective, patient-specific treatments when conventional options have failed. In his landmark 2019 study, Bangi introduced the "hindgut" platform—a robotics-based, high-throughput system—to screen for therapies targeting a patient’s KRAS-mutant metastatic colorectal cancer. This approach identified the combination of trametinib plus zoledronate, which produced a strong partial response that remained stable for 11 months, a striking result for an otherwise refractory case. The work has garnered over 107 citations, underscoring its influence on precision oncology. Bangi further demonstrated the versatility of his methodology in a 2021 study, where he used a *Drosophila* platform to discover a novel personalized therapy for a patient with adenoid cystic carcinoma, a rare and notoriously difficult-to-treat salivary gland cancer. By bridging basic fly genetics with urgent clinical needs, Bangi has established a powerful paradigm for functional drug testing, offering new hope for patients with limited options.
Research Focus
Key Achievements
Top Papers
- 1
- 2